SLC5A2 and atherosclerosis: Since 2019, the American Diabetes Association has recommended sodium–glucose cotransporter 2 (SGLT‐2) inhibitors or glucagon‐like peptide 1 (GLP‐1) receptor agonists with demonstrated CVD benefit for adults with established atherosclerotic CVD (ASCVD) [5].